Business, energy, technology, markets and global industry news from Business News Today

Agenus Inc.

PharmaDeviceNews Agenus Inc.
Pharma & Biotech

Agenus BOTBAL survival data challenges expectations in MSS metastatic colorectal cancer

Explore how Agenus BOTBAL achieved 33% three-year survival in refractory MSS colorectal cancer and what Phase 3 must prove next.

Read More
Representative image: Oncology specialists review colorectal cancer scans and survival data as Agenus prepares to present three-year BOT+BAL findings in MSS metastatic colorectal cancer at ESMO GI 2026.
Pharma & Biotech

Agenus prepares ESMO GI 2026 survival update as BOT+BAL enters its Phase 3 test

Read how Agenus’ three-year BOT+BAL survival update could reshape expectations in refractory MSS metastatic colorectal cancer.

Read More
Representative image: A clinical researcher reviews liver cancer scan data in an oncology research setting, illustrating the growing focus on Agenus’ botensilimab and balstilimab combination in post-immunotherapy hepatocellular carcinoma treatment.
Pharma & Biotech

Can Agenus turn botensilimab and balstilimab into a serious post-ICI liver cancer contender?

Post-ICI liver cancer has few strong options. Agenus’ BOT plus BAL data raise the next question: can durability survive larger trials?

Read More
Pharma & Biotech

Is botensilimab finally ready for a bigger melanoma spotlight? Agenus bets on ASCO 2026

Agenus will unveil first Phase 2 botensilimab melanoma data at ASCO 2026. Read why the update could reshape sentiment around its checkpoint platform.

Read More
Representative image of immunotherapy research in gastroesophageal cancer, illustrating why Agenus’s AACR 2026 update on botensilimab, balstilimab, and agenT-797 is drawing attention in the post-PD-1 refractory treatment landscape.
Pharma & Biotech

What the Agenus-MiNK Therapeutics combination reveals about the next phase of GI cancer immunotherapy

Agenus brings botensilimab, balstilimab, and agenT-797 to AACR 2026. Read why this refractory GEC update matters and what risks remain.

Read More
Pharma & Biotech

What Agenus’ BOT and BAL biomarker work reveals about rescuing immunologically cold tumors

Agenus’ AACR-IO biomarker data reframes inflammation as a key determinant in cold tumor immunotherapy. Find out why this could reshape checkpoint strategies.

Read More